Lumretuzumab
- Generic Name
- Lumretuzumab
- Drug Type
- Biotech
- CAS Number
- 1448327-63-6
- Unique Ingredient Identifier
- Y6M3205516
- Background
Lumretuzumab has been used in trials studying the treatment of Neoplasms, Breast Cancer, Squamous Non-Small Cell Lung Cancer, and Non-Squamous Non-Small Cell Lung Cancer.
A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous Histology
Phase 1
Terminated
- Conditions
- Squamous Non-Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2014-07-30
- Last Posted Date
- 2017-01-25
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 12
- Registration Number
- NCT02204345
A Study to Evaluate Lumretuzumab in Combination With Pertuzumab and Paclitaxel in Participants With Metastatic Breast Cancer Expressing Human Epidermal Growth Factor Receptor (HER) 3 and HER2 Protein
Phase 1
Completed
- Conditions
- Breast Cancer
- Interventions
- First Posted Date
- 2013-08-07
- Last Posted Date
- 2017-09-12
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 66
- Registration Number
- NCT01918254
- Locations
- π«π·
Institut Curie; Oncologie Medicale, Paris, France
π©πͺUniversitaetsklinikum Essen; Westdeutsches Tumorzentrum; Innere Klinik (Tumorforschung), Essen, Germany
πͺπΈHospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona, Spain
A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin
Phase 1
Completed
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2011-11-30
- Last Posted Date
- 2017-01-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 145
- Registration Number
- NCT01482377
- Locations
- π³π±
Academ Ziekenhuis Groningen; Medical Oncology, Groningen, Netherlands
π°π·National Cancer Center, Gyeonggi-do, Korea, Republic of
π³π±Antoni van Leeuwenhoek Ziekenhuis, Amsterdam, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
Β© Copyright 2025. All Rights Reserved by MedPath